Autolus Therapeutics, a biopharmaceutical company specializing in next-generation T cell therapies, will release its first quarter 2026 financial results and operational highlights on May 14, 2026, before U.S. markets open. The company will host a conference call and webcast at 8:30am EDT to discuss the results and provide a business update. Autolus is known for its marketed therapy AUCATZYL® and is developing treatments for cancer and autoimmune diseases. This report will give investors insight into the company’s recent performance and strategic direction.
After the US and Iran reached a deal expected to reopen the Strait of Hormuz, the world's largest tanker owner, Mitsui OSK Lines, cautions that shipping companies will wait for proof the agreement works before resuming normal traffic. The strait is c...
YieldMax ETFs have announced their weekly distributions for Group 1 ETFs, with distribution rates ranging from about 25% to over 65%. These ETFs focus on option income strategies across sectors like semiconductors, AI, crypto, and metals. Investors s...
QTREX Quantum Ltd announced that its Additively Manufactured Electronics (AME) technology achieved a 97% yield validation at a major U.S. interconnect manufacturer. This milestone confirms the technology's readiness for high-demand production environ...
Clean Energy Fuels Corp. secured contracts to design and install liquefied natural gas (LNG) fueling systems in Puerto Rico, supporting a pharmaceutical manufacturer and P.R. Energy Partners' luxury residential and hotel operations. These projects wi...
Epson introduced the WorkForce Enterprise AM-C10000, a high-speed color multifunction printer capable of printing 100 ISO pages per minute, designed for busy offices and print services requiring precise color control. It supports heavy workloads with...
